Compare IMU which has 4 clinical trials (3 X phase 1A and 1 X Phase 1B) and CHM (3 X Phase 1B and 1 X Phase 1A) and CHM is massively undervalued.
IMU has an enterprise value of $420m versus CHMs $10m….CHM is crazy good value and I would say the pipeline is superior to IMU. Go figure.
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment, page-7
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(4.17%) |
Mkt cap ! $11.21M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $2.657K | 235.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1428738 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 1161817 | 4 |
View Market Depth
| Last trade - 11.54am 06/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |